218 related articles for article (PubMed ID: 31855165)
1. Effects of Pharmacotherapy Treatment on Patient-Reported Outcomes in a Narcolepsy and Idiopathic Hypersomnia Cohort.
Pascoe M; Bena J; Foldvary-Schaefer N
J Clin Sleep Med; 2019 Dec; 15(12):1799-1806. PubMed ID: 31855165
[TBL] [Abstract][Full Text] [Related]
2. Benefits and risk of sodium oxybate in idiopathic hypersomnia versus narcolepsy type 1: a chart review.
Leu-Semenescu S; Louis P; Arnulf I
Sleep Med; 2016 Jan; 17():38-44. PubMed ID: 26847972
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and side-effect profile of stimulant therapy as monotherapy and in combination in the central hypersomnias in clinical practice.
Thakrar C; Patel K; D'ancona G; Kent BD; Nesbitt A; Selsick H; Steier J; Rosenzweig I; Williams AJ; Leschziner GD; Drakatos P
J Sleep Res; 2018 Aug; 27(4):e12627. PubMed ID: 29047171
[TBL] [Abstract][Full Text] [Related]
4. Narcolepsy, idiopathic hypersomnolence and related conditions.
Quinnell TG; Smith IE
Clin Med (Lond); 2011 Jun; 11(3):282-6. PubMed ID: 21902087
[No Abstract] [Full Text] [Related]
5. Sodium oxybate improves excessive daytime sleepiness in narcolepsy.
Black J; Houghton WC
Sleep; 2006 Jul; 29(7):939-46. PubMed ID: 16895262
[TBL] [Abstract][Full Text] [Related]
6. Quality of life and procrastination in post-H1N1 narcolepsy, sporadic narcolepsy and idiopathic hypersomnia, a Swedish cross-sectional study.
Wasling HB; Bornstein A; Wasling P
Sleep Med; 2020 Dec; 76():104-112. PubMed ID: 33152582
[TBL] [Abstract][Full Text] [Related]
7. Sleeping through a pandemic: impact of COVID-19-related restrictions on narcolepsy and idiopathic hypersomnia.
Nigam M; Hippolyte A; Dodet P; Gales A; Maranci JB; Al-Youssef S; Leu-Semenescu S; Arnulf I
J Clin Sleep Med; 2022 Jan; 18(1):255-263. PubMed ID: 34314345
[TBL] [Abstract][Full Text] [Related]
8. Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav
Heo YA
CNS Drugs; 2022 May; 36(5):541-549. PubMed ID: 35357671
[TBL] [Abstract][Full Text] [Related]
9. Precision Medicine for Idiopathic Hypersomnia.
Arnulf I; Leu-Semenescu S; Dodet P
Sleep Med Clin; 2019 Sep; 14(3):333-350. PubMed ID: 31375202
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial.
Dauvilliers Y; Roth T; Bogan R; Thorpy MJ; Morse AM; Roy A; Dubow J; Gudeman J
Sleep; 2023 Nov; 46(11):. PubMed ID: 37246913
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study.
Dauvilliers Y; Arnulf I; Foldvary-Schaefer N; Morse AM; Šonka K; Thorpy MJ; Mignot E; Chandler P; Parvataneni R; Black J; Sterkel A; Chen D; Skobieranda F; Bogan RK
Lancet Neurol; 2022 Jan; 21(1):53-65. PubMed ID: 34942138
[TBL] [Abstract][Full Text] [Related]
12. Differentiation of central disorders of hypersomnolence with manual and artificial-intelligence-derived polysomnographic measures.
Cesari M; Egger K; Stefani A; Bergmann M; Ibrahim A; Brandauer E; Högl B; Heidbreder A
Sleep; 2023 Feb; 46(2):. PubMed ID: 36455881
[TBL] [Abstract][Full Text] [Related]
13. Psychological health in central hypersomnias: the French Harmony study.
Dauvilliers Y; Paquereau J; Bastuji H; Drouot X; Weil JS; Viot-Blanc V
J Neurol Neurosurg Psychiatry; 2009 Jun; 80(6):636-41. PubMed ID: 19211597
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia.
Morse AM; Dauvilliers Y; Arnulf I; Thorpy MJ; Foldvary-Schaefer N; Chandler P; Chen A; Hickey L; Black J; Bogan RK
J Clin Sleep Med; 2023 Oct; 19(10):1811-1822. PubMed ID: 37409509
[TBL] [Abstract][Full Text] [Related]
15. Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia.
Junnarkar G; Allphin C; Profant J; Steininger TL; Chen C; Zomorodi K; Skowronski R; Black J
Expert Opin Drug Discov; 2022 Feb; 17(2):109-119. PubMed ID: 34818123
[TBL] [Abstract][Full Text] [Related]
16. Comorbid parasomnias in narcolepsy and idiopathic hypersomnia: more REM than NREM parasomnias.
Leu-Semenescu S; Maranci JB; Lopez R; Drouot X; Dodet P; Gales A; Groos E; Barateau L; Franco P; Lecendreux M; Dauvilliers Y; Arnulf I
J Clin Sleep Med; 2022 May; 18(5):1355-1364. PubMed ID: 34984974
[TBL] [Abstract][Full Text] [Related]
17. Observation and Interview-based Diurnal Sleepiness Inventory for measurement of sleepiness in patients referred for narcolepsy or idiopathic hypersomnia.
Peter-Derex L; Subtil F; Lemaitre G; Ricordeau F; Bastuji H; Bridoux A; Onen F; Onen SH
J Clin Sleep Med; 2020 Sep; 16(9):1507-1515. PubMed ID: 32406372
[TBL] [Abstract][Full Text] [Related]
18. Central Disorders of Hypersomnolence: Association with Fatigue, Depression and Sleep Inertia Prevailing in Women.
Nevsimalova S; Skibova J; Galuskova K; Prihodova I; Dostalova S; Maurovich-Horvat E; Šonka K
Brain Sci; 2022 Nov; 12(11):. PubMed ID: 36358417
[TBL] [Abstract][Full Text] [Related]
19. Lipocalin-type prostaglandin D synthase levels increase in patients with narcolepsy and idiopathic hypersomnia.
Wang P; Li Q; Dong X; An H; Li J; Zhao L; Yan H; Aritake K; Huang Z; Strohl KP; Urade Y; Zhang J; Han F
Sleep; 2021 Apr; 44(4):. PubMed ID: 33175978
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy.
Xyrem International Study Group
J Clin Sleep Med; 2005 Oct; 1(4):391-7. PubMed ID: 17564408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
